Losartan reduces the medical burden and costs associated with End-Stage Renal Disease (ESRD). Implications from the RENAAL Study for Germany.

被引：0
|
作者：
Liebl, A
Carides, GW
Gerth, WC
Krobot, KJ
机构：
[1] Diabeteszentrum, Fachklin Bad Heilbrunn, Bad Heilbrunn, Germany
[2] Merck & Co Inc, Whitehouse Stn, NJ USA
[3] MSD Sharp & Dome GmbH, Haar, Germany
来源：
DIABETOLOGIA | 2002年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
934
引用
收藏
页码：A301 / A302
页数：2
相关论文
共 50 条
  • [1] Losartan reduces the costs associated with diabetic end-stage renal disease - The RENAAL study economic evaluation
    Herman, WH
    Shahinfar, S
    Carides, GW
    Dasbach, F
    Gerth, WC
    Alexander, CM
    Cook, JR
    Keane, WF
    Brenner, BM
    DIABETES CARE, 2003, 26 (03) : 683 - 687
  • [2] Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation
    Herman, WH
    Shahinfar, S
    Carides, GW
    Dasbach, EJ
    Gerth, WC
    Alexander, CM
    Cook, JR
    Keane, WF
    Brenner, BM
    DIABETES, 2002, 51 : A28 - A28
  • [3] Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective
    Burgess, ED
    Carides, GW
    Gerth, WC
    Marentette, MA
    Chabot, I
    CANADIAN JOURNAL OF CARDIOLOGY, 2004, 20 (06) : 613 - 618
  • [4] Losartan reduces the burden of ESRD: public health implications from the RENAAL study for the European Union
    Gerth, WC
    Hannedouche, T
    Martinez-Castelao, A
    Remuzzi, G
    Viberti, GC
    Nocea, G
    Carides, GW
    EUROPEAN HEART JOURNAL, 2002, 23 : 728 - 728
  • [5] The impact of losartan on the lifetime incidence of end-stage renal disease and associated costs: Lifetime projections based on the RENAAL study.
    Keane, WF
    Carides, GW
    Shahinfar, S
    Dasbach, EJ
    Gerth, WC
    Alexander, CM
    Herman, WH
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 264A - 265A
  • [6] Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union
    Gerth, WC
    Remuzzi, G
    Viberti, G
    Hannedouche, T
    Martinez-Castelao, A
    Shahinfar, S
    Carides, GW
    Brenner, B
    KIDNEY INTERNATIONAL, 2002, 62 : S68 - S72
  • [7] Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL Study for the European Union
    Gerth, WC
    Viberti, G
    Remuzzi, G
    Martinez-Castelao, A
    Hannedouche, T
    Carides, G
    DIABETOLOGIA, 2002, 45 : A302 - A302
  • [8] Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study
    Tershakovec, Andrew M.
    Keane, William F.
    Zhang, Zhongxin
    Lyle, Paulette A.
    Appel, Gerald B.
    McGill, Janet B.
    Parving, Hans-Henrik
    Cooper, Mark E.
    Shahinfar, Shahnaz
    Brenner, Barry M.
    DIABETES CARE, 2008, 31 (03) : 445 - 447
  • [9] Losartan reduces the burden and cost of diabetic end-stage renal disease in Greece
    Stafylas, P. C.
    Sarafidis, P. A.
    Lasaridis, A. N.
    Grekas, D. M.
    Dombros, N. V.
    Tsakni, E.
    Aletras, V. H.
    Niakas, D. A.
    Bakris, G. L.
    JOURNAL OF HYPERTENSION, 2006, 24 : S124 - S124
  • [10] Losartan reduces the costs of diabetic end-stage renal disease: An Asian perspective
    Seng, WK
    Hwang, SJ
    Han, DC
    Teong, CC
    Chan, J
    Burke, TA
    Carides, GW
    Choi, YJ
    NEPHROLOGY, 2005, 10 (05) : 520 - 524
12345